Recherche
-
Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data
(Journal of Medical Economics. vol. 24, n° 1, pp. 1-37, 2021-08-23)Article de revueLibre accès -
Current status and practical considerations of artificial intelligence use in screening and diagnosing retinal diseases: Vision Academy retinal expert consensus
(Current Opinion in Ophthalmology. vol. 34, n° 5, pp. 403-413, 2023-09-01)Article de revueLibre accès -
TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
(Ophthalmology Science. vol. 1, n° 4, 2021-12)Article de revueLibre accès -
The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
(Current Opinion in Ophthalmology. vol. 34, n° 5, pp. 396-402, 2023-09-01)Article de revueLibre accès -
Microperimetry to predict disease progression in eyes at high risk of age-related macular degeneration disease: The PREVISION study
(Acta Ophthalmologica. vol. 101, n° 2, pp. e135-e142, 2023-03)Article de revueLibre accès -
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
(Ophthalmology and Therapy. vol. 13, n° 3, pp. 725-738, 2024-03-01)Article de revueLibre accès -
Retinal microvasculature and incident dementia over 10 years: The Three-City-Alienor cohort
(Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. vol. 15, n° 4, pp. e12480, 2023-10)Article de revueLibre accès -
Two-year outcomes of the APOLLON observational study of intravitreal aflibercept monotherapy in France in patients with diabetic macular edema
(Scientific Reports. vol. 12, n° 1, 2022-10-29)Article de revueLibre accès -
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
(The Lancet. vol. 402, n° 10411, pp. 1434-1448, 2023-10-21)Article de revue -
Age-related macular degeneration and loss of autonomy : the Alienor-3C Study
Communication dans un congrès